Efficacy and Safety of Antiintegrin Antibody for Inflammatory Bowel Disease

A Systematic Review and Meta-Analysis

Lianjie Lin, MD, PhD, Xiang Liu, MD, PhD, Dongyu Wang, MD, and Changqing Zheng, MD, PhD

INTRODUCTION

Crohn disease (CD) and ulcerative colitis (UC), the 2 most prevalent forms of inflammatory bowel disease (IBD), affect more than 2.5 million people of European ancestry, whereas increasing frequencies are being reported in the developing world. Currently, approved therapies for IBD have considerable limitations, as they frequently display only moderate efficacy and are often associated with unacceptable risk of serious adverse events (SAEs), constituting a clear need to develop new treatment options. Indeed, it was recently reported that 20% to 40% of CD and 40% of UC patients will ultimately prove refractive to conventional approaches using antitumor necrosis factor (anti-TNF)-α, illustrating the clear need for new treatment strategies.

CD and UC are both characterized by persistent inflammation, which is mediated by the migration of proinflammatory T cells into the gastrointestinal tract. The repertoire of receptors expressed on the T-cell surface plays a critical role in maintaining this chronic inflammatory state. Naïve T cells encounter antigen in peripheral lymphoid organs, driving clonal expansion of effector T cells, which then migrate from the blood to affected tissues and back to the blood, creating the perpetual state of activation observed in chronic inflammatory disorders. Activated effector T cells home from the blood to affected tissues via tightly regulated cell–cell interactions. T-cell infiltration in the gut is dependent upon interactions between surface-expressed α4β7 integrins and mucosal addressin cell adhesion molecule (MAdCAM-1), present on endothelial cells. The critical role of this interaction in extravasation of T cells into the GI tract makes α4β7 integrins a good target for therapy.

Several monoclonal antibodies that function to block α4β7 integrins have been developed: natalizumab is specific for the α4 integrin subunit (Tysabri; Biogen Idec and Elan Pharmaceuticals, Cambridge, Massachusetts, USA), vedolizumab (Entyvio, Millennium Pharmaceuticals, Cambridge, Massachusetts, USA, MLN02, LDP02, MLN0002; Millennium Pharmaceuticals) is directed against an epitope comprising the α4β7 heterodimer; natalizumab, which recognizes the α4 integrin subunit; etrolizumab, which is specific for the β7 subunit—in the treatment of CD and ulcerative colitis (UC).

CD patients receiving either vedolizumab or natalizumab demonstrated a modest increase in remission rate, when compared with that of the placebo group. Further, although both treatments reduced the CDAI slightly, the observed clinical response was less robust than that of the remission rate. UC patients treated with vedolizumab and natalizumab were found to show more prominent increases in both remission and clinical response, compared with placebo, than patients with CD. Etrolizumab, however, was not found to significantly affect either response or remission rates in UC patients.

Biologics targeting integrins show promise as therapeutics in the treatment of inflammatory bowel disease in patients who are either nonresponsive or intolerant to traditional approaches, though further research is necessary to optimize treatment efficacies.
MATERIALS AND METHODS

Search Strategy and Selection Criteria

In conducting this meta-analysis, we followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.\(^6\) We systematically searched Medline, Embase, the Cochrane Library, and Google Scholar through October 31, 2013 for various combinations of the following keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, integrin, vedolizumab, natalizumab, etrolizumab, and monoclonal antibody. Furthermore, the reference lists of all relevant publications were searched by hand. This study did not involve human subjects, so informed consent was not required. In addition, no approval was required from any institutional review board.

Inclusion criteria for this meta-analysis required that the study be: original, excluding review articles and meta-analyses; a randomized controlled trial of an anti-\(\alpha_4\beta_7\) antibody as monotherapy; participants demonstrate active IBD. Non-English publications, studies employing a single arm, and those comprising retrospective data were excluded from this analysis.

The following information was extracted from studies that met the inclusion criteria: the name of the first author, year of publication, study design, demographic data of subjects, regimen (dose and frequency) of anti-\(\alpha_4\beta_7\) integrin antibody, clinical remission rate, clinical response rate, adverse events, and SAEs.

Data Extraction and Quality Assurance

Studies in this meta-analysis were identified by 2 independent reviewers using the above search strategy. Uncertainties regarding eligibility were resolved by consensus. The following information was extracted from studies that met the inclusion criteria: the name of the first author, year of publication, study design, demographic data of subjects, regimen (dose and frequency) of anti-\(\alpha_4\beta_7\) integrin antibody, clinical remission rate, clinical response rate, adverse events, and SAEs.

Table 1. Quality Assessment of Included Studies Using the Delphi List

| First Author (Year) | Was a Method of Randomization Used? | Were the Groups Similar at Baseline Regarding the Most Important Prognostic Indicators? | Were the Eligibility Criteria Specified? | Was the Outcome Assessor Blinded? | Was the Care Provider Blinded? | Was the Patient Blinded? | Were Point Estimates and Measures of Variability Presented for the Primary Outcome Measures? | Did the Analysis Include an Intention-to-Treat Analysis? |
|---------------------|-----------------------------------|---------------------------------------------------------------|----------------------------------------|----------------------------------|------------------------------|--------------------------|-------------------------------------------------------------|-----------------------------------------------|
| CD                  |                                    |                                                               |                                        |                                  |                              |                          |                                                              |                                               |
| Sandborn (2013)\(^1\) | Y                                  | Y                                                             | Y                                      | Y                                | Y                            | Y                        | Y                                                            | N                                             |
| Feagan (2008)\(^2\) | Y                                  | Y                                                             | Y                                      | Y                                | Y                            | Y                        | Y                                                            | N                                             |
| Targan (2007)\(^3\) | Y                                  | Y                                                             | Y                                      | Y                                | Y                            | Y                        | Y                                                            | N                                             |
| Sandborn (2005)\(^4\) | Y                                  | Y                                                             | Y                                      | Y                                | Y                            | Y                        | Y                                                            | N                                             |
| Ghosh (2003)\(^5\)  | Y                                  | Y                                                             | Y                                      | Y                                | Y                            | Y                        | Y                                                            | N                                             |
| Gordon (2001)\(^6\) | Y                                  | Y                                                             | Y                                      | Y                                | Y                            | Y                        | Y                                                            | N                                             |
| UC                  |                                    |                                                               |                                        |                                  |                              |                          |                                                              |                                               |
| Rutgeerts (2013)\(^7\) | Y                                  | Y                                                             | Y                                      | Y                                | Y                            | Y                        | Y                                                            | N                                             |
| Feagan (2013)\(^8\) | Y                                  | Y                                                             | Y                                      | Y                                | Y                            | Y                        | Y                                                            | N                                             |
| Parikh (2012)\(^9\) | Y                                  | Y                                                             | Y                                      | N                                | N                            | N                        | Y                                                            | N                                             |
| Feagan (2005)\(^10\) | Y                                 | Y                                                              | Y                                      | Y                                | Y                            | Y                        | Y                                                            | N                                             |

CD = Crohn disease, UC = ulcerative colitis

Outcome Measures

The primary outcome measurement was the percent of patients achieving remission, as defined by the parameters laid out by each individual study. The secondary outcomes were clinical response rates, also as defined by the primary study, and adverse events. Briefly, for the CD studies, remission was universally defined as a CD Activity Index (CDAI) score <150, whereas defined clinical response corresponded to a decrease of 70 points in CDAI in all studies, except for Sandborn et al\(^{11}\), which required a decrease of 100 points in CDAI\(^{12–16}\).

For UC studies, the threshold for remission was universally defined as a Mayo Clinic score <2, with individual subscores <1. A decrease in the Mayo Clinic score >3 points, >30% from baseline, accompanied by >1 point reduction in the rectal bleeding subscore, or an absolute rectal bleeding subscore of 0–1, generally constituted clinical response.\(^{17–20}\) In 1 study, however, clinical response was defined by a Mayo Clinic score reduction >2 points and 25% from baseline measurements.\(^{20}\)

Statistical Analysis

The relative effect of treatment and placebo on clinical remission, response rates, and SAEs were compared and expressed as odds ratios (ORs), with 95% confidence intervals (CIs). ORs, calculated for binary outcomes, were compared between treatment and control groups. For the rate of clinical remission and response, an OR >1 indicates that the treatment group is favored, whereas for SAEs, an OR <1 indicates that the treatment group is favored (ie, associated with fewer adverse events). Study heterogeneity was identified by \(\chi^2\), using Cochran Q statistic, and quantified by \(I^2\), which determines the percent of the total variability that cannot be ascribed to chance. For analyses in which heterogeneity (\(I^2 > 50\%\)) was detected, a random-effects model was used. A fixed-effects model was employed in the absence of significant heterogeneity. Pooled ORs resulting in a 2-sided \(P\) value <0.05 were considered statistically significant. Sensitivity analysis, for both
primary and secondary outcomes, was carried out using the leave-one-out approach.

Publication bias was assessed by funnel-plot analysis and Egger test. For funnel-plot analysis, the absence of publication bias was determined by assessing the ability of the data points to fit within a symmetric, funnel-shaped distribution. Evaluation by Egger linear regression was also employed, where 1-tailed $P$ values $>$0.05 indicated a low risk of publication bias. All analyses were performed using Comprehensive Meta-Analysis statistical software, version 2.0 (Biostat, Englewood, NJ).

RESULTS

Literature Search, Evaluation for Study Inclusion, and Quality Assessment

As illustrated in Figure 1, initial database screens yielded 192 candidate studies. Upon further examination, 161 of these studies were found to be unsuited to the purpose of this meta-analysis, based on inclusion criteria, and were thus excluded. Twenty-one of the remaining 31 trials were also subsequently excluded, because the intervention combined antiintegrin antibodies with anti-TNF, rather than utilizing monotherapy ($n=1$); the intervention failed to employ an antibody targeting any or all components of the $\alpha_4\beta_7$ integrin ($n=20$). The remaining 10 randomized controlled trials comprise this meta-analysis.11–20

Study Characteristics

A total of 10 studies are included in this report—6 focusing on CD and 4 on UC. Table 2 summarizes the baseline characteristics, which were relatively similar for each study included in this analysis. The number of study participants receiving treatment and placebo ranged from 18 to 724 (total = 1513) and 12 to 250 (total = 965), respectively. Although 4 studies in patients with CD examined the effects of natalizumab, 2 tested vedolizumab. In these studies, dosing schedules varied between those utilizing a single 300 mg dose of therapy,11,13,14 and those using a variable concentration, which ranged from 0.5 to 6 mg/kg.12,15,16 In addition to the dosing regimens, these studies also demonstrated variations in the frequency and absolute number of infusions. Three of the 4 studies examining efficacy of anti-$\alpha_4\beta_7$ antibody in UC patients employed vedolizumab;18–20 only Rutgeerts et al17 tested etrolizumab. Although 1 study tested a single 300 mg dose of vedolizumab,18 the other 2 used a variable concentration, which ranged from 0.5 to 10 mg/kg. As was noted for the CD studies, these

The methodological approaches employed in all 10 studies were deemed to be of high quality by the Delphi list of criteria (Table 1). With the exception of Parikh et al19, all the studies were randomized and double-blinded for assessor, provider, and patient. Four of the 10 trials did not include an intent-to-treat analysis.

FIGURE 1. Flowchart of study selection. RCT = randomized controlled trial.
treatment schedules varied both in frequency and number (data not shown). Primary and secondary outcomes for all studies are summarized in Table 3. It should be noted that more patients were evaluated for adverse events than were assessed for primary and secondary outcomes. Sandborn (2013)\(^1\) and Feagan (2013)\(^2\) both included 2 cohorts to assess safety, which resulted in the disparity.

### Efficacy of Anti-α4β7 Antibody

Six studies in CD patients were compared with regard to the primary outcome of clinical remission. Because there was evidence of moderate heterogeneity within these studies (Q statistic = 10.99, \(P = 54.50\%\), \(P = 0.052\), a random-effects model was applied. The difference in the clinical remission rate favored the treatment group over placebo (OR 2.108, 95% CI 1.460–3.043, \(P < 0.001\)) (Figure 2A). Five of the 6 studies involving CD patients were included in the analysis of clinical response rates. As shown in Figure 2B, treatment resulted in a higher frequency of clinical response than that observed for the placebo control (OR 1.607, 95% CI 1.327–1.9473, \(P < 0.001\)). Because there was no evidence of heterogeneity in these 5 studies (Q statistic = 6.15, \(F = 34.99\%\), \(P = 0.188\)), a fixed-effects model was applied.

### TABLE 3. Summary of the Clinical Remission Rate, Clinical Response Rate, and SAEs

| First Author (Year) | Time of Point of Efficacy Evaluation, wk | Total Patients | Induction Period, wk | Treatment Group | Placebo Group | Treatment Group | Placebo Group |
|---------------------|------------------------------------------|---------------|----------------------|----------------|---------------|----------------|---------------|
|                     | n                                        | n             |                      | Patient Number | Age (Mean ± SD, y) | Gender (% of Males) | Patient Number | Age (Mean ± SD, y) | Gender (% of Males) |
| CD                  |                                          |               |                      |                |               |                |                |
| Sandborn (2013)     |                                          | 1115          | 2                    | 200            | 36.3 ± 11.6   | 48             | 148            | 38.6 ± 13.2   | 47             |
| Feagan (2005)       |                                          | 185           | 4                    | 62             | 32 ± 12.67    | 40             | 58             | 34.5 ± 11.26  | 52             |
| Targan (2007)       |                                          | 509           | 8                    | 65             | 38.5 ± 13.07  | 48             | 65             | 38.8 ± 13.07  | 48             |
| Sandborn (2005)     |                                          | 905           | 8                    | 259            | 38.1          | 41             | 259            | 38.1          | 41             |
| Ghosh (2003)        |                                          | 248           | 4                    | 724            | 38 ± 12       | 43             | 181            | 39 ± 14       | 40             |
| Gordon (2001)       |                                          | 30            | 2                    | 68             | 36 (18, 66)   | 40             | 63             | 34 (18, 68)   | 48             |
| Rutgeerts (2013)    |                                          | 38            | 8                    | 18             | 36 ± 13.2     | 39             | 12             | 34.4 ± 8.8    | 43             |
| Feagan (2013)       |                                          | 895           | 2                    | 18             | 44 ± 14       | 72             | 5              | 39 ± 19       | 60             |
| Parikh (2012)       |                                          | 46            | 12                   | 225            | 40.1 ± 13.1   | 59             | 149            | 41.2 ± 12.5   | 62             |
| Feagan (2005)       |                                          | 181           | 4                    | 37             | 41 (19, 69)   | 43             | 9              | 33 (21, 51)   | 33             |

CD = Crohn disease, n = number of patients, n/a = not available, SAE = serious adverse events, UC = ulcerative colitis.
Three of the four studies in UC patients were included for analysis of clinical remission (Figure 3A). Because no heterogeneity was detected, a fixed-effects model was applied (Q statistic = 2.28, \(I^2 = 12.42\%\), \(P = 0.319\)). The difference in clinical remission rate between the treatment and placebo groups showed a clear advantage in patients receiving antibody (OR 2.839, 95% CI 1.656–4.867, \(P < 0.001\)) (Figure 3A). For analysis of clinical response rates, all 4 of UC studies were included. Again, a fixed-effects model was employed, as there was no evidence of heterogeneity among the studies (Q statistic = 4.75, \(I^2 = 36.80\%\), \(P = 0.191\)). Patients receiving treatment were found to demonstrate a higher frequency of clinical responses than those receiving placebo (OR 2.609, 95% CI 1.836–3.709, \(P < 0.001\)) (Figure 3B).

### Safety of Anti-\( \alpha\)-4\beta7 Antibody

Five of the 6 studies focused on CD were assessed with regard to SAEs associated with treatment (Figure 2C). Evidence of significant heterogeneity between the studies resulted in use of a random-effects model (Q statistic = 13.78, \(I^2 = 70.98\%\), \(P = 0.008\)). No significant difference was detected in the SAE rate of the treatment group, when compared with that of the placebo control group (OR 0.940, 95% CI 0.547–1.614, \(P = 0.823\)) (Figure 2C). As no heterogeneity was detected among the 4 UC studies included for analysis of SAE, a fixed-effects model was applied (Q statistic = 0.56, \(I^2 = 0\%\), \(P = 0.905\)). As was observed for CD patient groups, treatment did not significantly affect the rate of SAE, compared with control, in studies of UC patients (OR 0.953, 95% CI 0.647–1.403, \(P = 0.807\)) (Fig. 3C).

A summary of adverse events reported by studies included in this meta-analysis is shown in Table 4. The most commonly reported adverse events were exacerbation of disease (ie, CD or UC) and headache. As mentioned previously, however, these effects were not found to be significantly different in the treatment group, compared with the control group. Additional reported adverse events, including nausea, infections, fatigue, and nasopharyngitis were also found to occur at similar rates between treatment and control groups. There was a higher frequency of adverse events in patients with CD than in those with UC. Overall, however, all treatments were found to be well tolerated.

### Sensitivity Analysis and Publication Bias

To evaluate the reliability of our meta-analytical data, we tested sensitivity using the ‘leave-one-out’ approach. As shown in Figure 4A, removal of any 1 study from the analysis of remission rates in CD patients does not significantly affect the

---

**FIGURE 2.** Efficacy and safety of anti-\( \alpha\)-4\beta7 antibody in the treatment of CD. Forest plot comparing the effect of anti-\( \alpha\)-4\beta7 antibodies on (A) the clinical remission rate, (B) the clinical response rate, and (C) the SAEs rate versus placebo control. 1st AU = first author, CD = Crohn disease, CI = confidence interval, Lower limit = lower bound of the 95% CI, Upper limit = upper bound of the 95% CI, SAE = serious adverse events.
outcome. Similarly, no one study was found to disproportionately influence the results obtained for remission rates in UC patients (Figure 4B). The constancy in direction and magnitude of the combined estimates, regardless of exclusion of individual studies, indicates that the meta-analysis had good reliability.

To ensure that there was no publication bias for this analysis, we employed Egger test. This test found no evidence of publication bias for clinical remission rates in either the CD studies (Figure 5A; t = 1.88, P = 0.068) or the UC studies (Figure 5B; t = 4.93, P = 0.064).

**DISCUSSION**

A large percentage of patients with moderate-to-severe IBD demonstrate refractory disease, either completely unresponsive to standard treatment regimens or unable to mount a durable response.\(^4\) Gut infiltration by T lymphocytes is well established as a mechanism of IBD pathogenesis. The molecular pathways that mediate this migration of lymphocytes into the GI tract is tightly regulated, involving coordinated interactions between several adhesion and signaling molecules (e.g., selectins, integrins, and chemokine receptors), expressed on the T-cell surface, with their corresponding ligands, on endothelial cells. Gut infiltration by T cells specifically requires interactions between surface-localized dimers, but affects interactions between surface-localized cell adhesion molecule-1 in the central nervous system. This additional effect is believed to play a role in the development of PML.\(^24\) Recently, a retrospective study found the risk of PML among natalizumab-treated patients to be directly linked to 3 factors: the presence of anti-John Cunningham ham virus antibodies, prior exposure to immunosuppressive drugs, and the duration of natalizumab treatment.\(^25\) Although vedolizumab specifically recognizes an epitope comprising both subunits of the α₄β₇ integrin, natalizumab is more generalized, targeting only the α₄ subunit. Because natalizumab targets α₄ inhibition is not limited to α₄β₇ heterodimers, but affects interactions between α₄β₁ and vascular cell adhesion molecule-1 in the central nervous system. This additional effect is believed to play a role in the development of a devastating neurological disorder, progressive multifocal leukoencephalopathy (PML), in a small cohort of patients receiving natalizumab.\(^24\) Recently, a retrospective study found the risk of PML among natalizumab-treated patients to be directly linked to 3 factors: the presence of anti-John Cunningham ham virus antibodies, prior exposure to immunosuppressive drugs, and the duration of natalizumab treatment.\(^25\) Although no patients in the studies examined here developed PML, the risk associated with natalizumab presents a clear advantage for the use of vedolizumab and etrolizumab. Though emergent antibody treatments were well tolerated, demonstrating a similar risk of developing SAE to that of the placebo controls. Interestingly, we found the antibodies to elicit a more consistent response in CD than in UC (Figures 2 and 3). The 1 exception to this observation was Rutgeerts (2013), which assessed efficacy of etrolizumab and showed greater efficacy in patients with UC. These differences may arise from variation in the moieties within α₄β₇ heterodimer targeted by the respective antibodies, though it is difficult to examine with any accuracy, as the number of patients treated with etrolizumab only represent 1.97% of the total number of patients assessed in this review. Further studies will be necessary to evaluate whether there is a difference in efficacy for antiintegrin therapies in the treatment of CD versus UC.
### TABLE 4. Summary of Adverse Events

| First Author | Group | CD or UC | Exacerbation | Infections | Headache | Nausea | Fatigue | Arthralgia | Pyrexia | Nausea-Like Illness | Respiratory Tract Infection | Cough | Anemia | Hypertension | C-reactive Protein Increased | Constipation | Dizziness | Colitis | Frequent Bowel Movements | Urinary Tract Infection | Blood in Stool | Back Pain |
|--------------|-------|----------|--------------|------------|----------|--------|--------|-----------|---------|---------------------|-----------------------------|------|-------|-------------|-----------------------------|------------|-----------|--------|---------------------------|-----------------------------|-------------|-----------|
| CD           |       |          |              |            |          |        |        |           |         |                     |                             |      |       |             |                             |            |           |        |                           |                             |             |           |
| Sandborn     | Tx    | 814      | 20.1         | 5.5        | 11.9     | 11.1   | 6.0    | 6.5       | 13.5    | 12.7    | 12.3               | 6.6                          |      |       |             |                             |            |           |        |                           |                             |             |           |
| Placebo      |       | 301      | 21.6         | 3.0        | 15.6     | 10.0   | 7.6    | 4.7       | 13.3    | 13.3    | 8.0                | 5.6                          |      |       |             |                             |            |           |        |                           |                             |             |           |
| Feagan       | (2013)| Tx       | 127          | 19         | 1        | 36     | 15     | 18        | 18      | 11      | 15                 | 11.1                         | 6.0  |       |             |                             |            |           |        |                           |                             |             |           |
| Placebo      |       | 58       | 19           | 3          | 24       | 19     | 12     | 19        | 7       | 5       | -                  | 6.0                          |      |       |             |                             |            |           |        |                           |                             |             |           |
| Targan       | (2007)| Tx       | 259          | 7          | 35       | 29     | 12     | 15        | 10      | 11      | 18                 | 6.0                          |      |       |             |                             |            |           |        |                           |                             |             |           |
| Placebo      |       | 250      | 13           | 30         | 21       | 9      | 12     | 7         | -       | 10      | 14                 | 8.0                          |      |       |             |                             |            |           |        |                           |                             |             |           |
| Sandborn     | (2005)| Tx       | 723          | 6          | 49       | 30     | 11     | 17        | 8       | 10      | -                  | 13.3                         |      |       |             |                             |            |           |        |                           |                             |             |           |
| Placebo      |       | 181      | 10           | 43         | 23       | 13     | 17     | 10        | 8       | -       | 14                 | -                            |      |       |             |                             |            |           |        |                           |                             |             |           |
| Ghosh        | (2003)| Tx       | 181          | 10         | 31       | 15     | 9      | -         | 10      | 14      | 10                 | -                            |      |       |             |                             |            |           |        |                           |                             |             |           |
| Placebo      |       | 63       | 13           | 32         | 17       | 16     | -      | 11        | -       | 8       | 8                  | -                            |      |       |             |                             |            |           |        |                           |                             |             |           |
| Gordon       | (2001)| Tx       | 18           | 39         | 50       | 22     | -      | -         | -       | -       | -                  | -                            |      |       |             |                             |            |           |        |                           |                             |             |           |
| Placebo      |       | 12       | 42           | 50         | 17      | -      | -      | -         | -       | -       | -                  | -                            |      |       |             |                             |            |           |        |                           |                             |             |           |
| UC           |       |          |              |            |          |        |        |           |         |         |                     |                             |      |       |             |                             |            |           |        |                           |                             |             |           |
| Rutgeerts    | Tx    | 38       | 42           | 45         | 32       | 16     | 13     | -         | 16      | 11      | 16                 | 5                            |      |       |             |                             |            |           |        |                           |                             |             |           |
| Placebo      |       | 10       | 80           | 40         | 20       | 10     | 10     | -         | 0       | 0       | 0                  | 20                           |      |       |             |                             |            |           |        |                           |                             |             |           |
| Feagan       | (2013)| Tx       | 620          | 15.6       | 19       | 12.9   | 5.6    | 6.1       | 5.3     | 9.0     | 12.9               | 8.4                          | 5.8  |       |             |                             |            |           |        |                           |                             |             |           |
| Placebo      |       | 275      | 21.1         | 2.9        | 10.2     | 3.6    | 6.9    | -         | 3.6     | 9.1     | 9.5                | 7.6                          | 4.7  |       |             |                             |            |           |        |                           |                             |             |           |
| Parikh       | (2012)| Tx       | 37           | 8          | 19       | -      | -      | -         | -       | 5       | 5                  | 8.8                          | 5.8  |       |             |                             |            |           |        |                           |                             |             |           |
| Placebo      |       | 9        | 44           | -          | 11       | -      | -      | -         | -       | 0       | 0                  | 11                           | 33   |       |             |                             |            |           |        |                           |                             |             |           |
| Feagan       | (2005)| Tx       | 118          | 43         | 3        | 19     | 22     | 7         | 11      | 9       | 14                 | -                            | -    |       |             |                             |            |           |        |                           |                             |             |           |
| Placebo      |       | 63       | 38           | 0          | 21       | 13     | 16     | 8         | 11      | 8       | 8                  | -                            | 2    |       |             |                             |            |           |        |                           |                             |             |           |

CD = Crohn disease, UC = ulcerative colitis.

*Data presented as percentage (%).
biologics targeting α4β7 have been previously reviewed, the rapidly changing nature of this field, coupled with the high volume of recent and ongoing clinical trials, demand further examination of the data.26,27

The results obtained in this meta-analysis, although promising, suffer from several caveats. Specifically, there was significant clinical heterogeneity associated with variation in the treatment regimens used (eg, therapy, duration, dosage). Furthermore, included studies only investigated anti-α4β7 monotherapy, rather than in conjunction with conventional IBD treatment strategies. It would be interesting to determine the safety and efficacy of such therapeutics in combination with other drugs, including immunosuppressants, anti-TNF antibodies, and other antibodies targeting proinflammatory cytokines.

Up to 40% of all UC and CD patients will prove refractive to conventional IBD treatment regimens.7 New approaches exploiting integrin-mediated extravasation of effector T cells could address this significant treatment gap. Furthermore, included studies only investigated anti-α4β7 monotherapy, rather than in conjunction with conventional IBD treatment strategies. It would be interesting to determine the safety and efficacy of such therapeutics in combination with other drugs, including immunosuppressants, anti-TNF antibodies, and other antibodies targeting proinflammatory cytokines.

Up to 40% of all UC and CD patients will prove refractive to conventional IBD treatment regimens.7 New approaches exploiting integrin-mediated extravasation of effector T cells could address this significant treatment gap. Furthermore, conventional therapies, such as anti-TNF and methotrexate, are associated with significant adverse events.26–31 Our study showed that antibodies specific for α4β7 integrins safely increased both the rates of clinical remission and response in both CD and UC patients. Evaluation of these therapies in a real-world setting, as well as in combination with other agents, will help to better assess their efficacy and safety relative to conventional approaches, such as anti-TNF-α. Regardless, antibodies aimed at blocking the chronic inflammation that is characteristic of IBD show enormous promise and represent a new era in therapeutics for immune-mediated disorders.
REFERENCES

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel disease with time, based on systematic review. Gastroenterology. 2012;142:46–54.

2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.

3. Mosli MH, Feagan BG. Vedolizumab for Crohn’s disease. Expert Opin Biol Ther. 2013;13:455–463.

4. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657.

5. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660–671.

6. Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447–458.

7. Gilroy L, Allen PB. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease? Clin Exp Gastroenterol. 2014;7:163–172.

8. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864–875.

9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65–W94.

10. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51:1235–1241.

11. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.

12. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6:1370–1377.

13. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672–1683.

14. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–1925.

15. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. N Engl J Med. 2003;348:24–32.

16. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology. 2001;121:268–274.

17. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb (7) in moderate to severe ulcerative colitis. Gut. 2013;62:1122–1130.

18. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.

19. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18:1470–1479.

20. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499–2507.

21. Salmi M, Jalkanen S. Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol Rev. 2005;206:100–113.

22. Engelhardt B, Briskin MJ. Therapeutic targeting of alpha 4-integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit? Eur J Immunol. 2005;35:2268–2273.

23. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmunise disease. N Engl J Med. 2003;348:68–72.

24. Barnia G, Clark DJ, Rivera-Nieves J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr Drug Targets. 2013;14:1490–1500.

25. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–1880.

26. Behm BW, Buckston SJ. Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2009;1:CD007571.

27. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;1:CD00697.

28. Lv R, Qiao W, Wu Z, et al. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One. 2014;9:e86692.

29. Fellermann K. Adverse events of tumor necrosis factor inhibitors. Dig Dis. 2013;31:374–378.

30. Patel V, Wang Y, MacDonald JK, et al. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD006884.

31. Chande N, Wang Y, MacDonald JK, et al. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;8:CD006618.